论文部分内容阅读
目的探讨阿托伐他汀联合曲美他嗪治疗冠状动脉粥样硬化性心脏病(CHD)患者的临床疗效和安全性。方法选取2012年12月至2015年3月茂名市中医院收治的240例CHD患者为研究对象,按随机数字表法将其分为对照组和观察组,各120例。对照组患者口服盐酸曲美他嗪片,观察组患者在对照组基础上采用阿托伐他汀钙片进行治疗,比较两组患者的临床疗效及不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);两组患者的不良反应发生率差异无统计学意义(P>0.05)。结论阿托伐他汀联合曲美他嗪治疗CHD患者临床疗效明显,且安全性较高。
Objective To investigate the clinical efficacy and safety of atorvastatin combined with trimetazidine in patients with coronary atherosclerotic heart disease (CHD). Methods A total of 240 CHD patients admitted from December 2012 to March 2015 in Maoming Traditional Chinese Medicine Hospital were enrolled in this study. They were divided into control group and observation group according to random number table method, each of 120 patients. Patients in the control group were treated with oral trimetazidine hydrochloride tablets. Patients in the observation group were treated with atorvastatin calcium tablets on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate of observation group was significantly higher than that of the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Atorvastatin combined with trimetazidine treatment of CHD patients with significant clinical efficacy and safety.